ID Biomedical Corporation of Quebec
BiotechID Biomedical Corporation of Quebec is a biotechnology company with 2 FDA-approved products.
ID Biomedical Corporation of Quebec's Key Drugs
ID Biomedical Corporation of Quebec's core commercial portfolio centers on Arepanrix — its most strategically important drugs approved in the last 15 years.
ID Biomedical Corporation of Quebec's Recent FDA Approvals
New NDA/BLA approvals for ID Biomedical Corporation of Quebec over the last two years — novel drugs only, excluding generics and label supplements.
ID Biomedical Corporation of Quebec's Therapeutic Areas
Disease areas where ID Biomedical Corporation of Quebec has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ID Biomedical Corporation of Quebec Pipeline Snapshot
Active clinical trials for ID Biomedical Corporation of Quebec across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Arepanrix leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2006-10-04
- Latest
- 2013-11-21
- Applications
- 2